Description:

O-Parib (Olaparib Tablets) is a potent, oral PARP (poly ADP-ribose polymerase) inhibitor used as targeted therapy for cancers associated with defective DNA repair mechanisms, such as BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. By inhibiting the PARP enzyme, O-Parib prevents cancer cells from repairing their damaged DNA, leading to cell death—especially in tumor cells with existing BRCA mutations.
Olaparib selectively inhibits the PARP enzyme, which is involved in DNA repair. In cancer cells with mutations in BRCA1 or BRCA2 genes, this inhibition leads to the accumulation of DNA damage, resulting in synthetic lethality and selective killing of cancer cells. It spares most normal cells, thereby reducing damage to healthy tissue.